{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04395677","nct_id":"NCT04395677","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04395677. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106","label":"AB-106 （DS-6051b）","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-06","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":173,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AB-106","otherNames":["DS-6051b"],"type":"DRUG"}],"last_update":"2026-02-06","lead_sponsor":"Nuvation Bio Inc.","official_title":"A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-06-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Best overall response (BOR) by IRC","timeFrame":"6 months"}],"references":[{"citation":"Li W, Zhang Y, Fan H, Yu Q, Ran F, Chen W, Zhou C. Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study. J Clin Oncol. 2026 Jun 20;44(18):1670-1675. doi: 10.1200/JCO-26-00434. Epub 2026 Apr 21.","pmid":"42013573","type":"DERIVED"},{"citation":"Perol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun;43(16):1920-1929. doi: 10.1200/JCO-25-00275. Epub 2025 Apr 3.","pmid":"40179330","type":"DERIVED"},{"citation":"Li W, Xiong A, Yang N, Fan H, Yu Q, Zhao Y, Wang Y, Meng X, Wu J, Wang Z, Liu Y, Wang X, Qin X, Lu K, Zhuang W, Ren Y, Zhang X, Yan B, Lovly CM, Zhou C. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol. 2024 Aug 1;42(22):2660-2670. doi: 10.1200/JCO.24.00731. Epub 2024 Jun 1.","pmid":"38822758","type":"DERIVED"}],"start_date":{"date":"2020-07-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","url":"https://clinicaltrials.gov/study/NCT04395677"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04395677"}